MSFrontier

T4MS

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
RecruitingNot a drug-phase studyEarly (CIS/RIS)NCT04798651

What it found

Still running

No result yet.

What was tested

Treatment tested

  • blood sample
  • cerebro-spinal fluid

What it measured

Main measures

  • Functional and phenotypical characterization of the blood and CSF lymphocytes in MS and CIS patients.

    At inclusion (day 0)

    Blood or spinal fluid markersImmune response

Other measures (10)

  • Quantification of disease activity scores

    At inclusion (day 0)

    Disability progression

  • Number of lesions

    At inclusion (day 0)

    MRI lesions

  • Size of lesions

    At inclusion (day 0)

    MRI lesions

  • Localisation of lesions

    At inclusion (day 0)

    MRI lesions

  • Types of lesions

    At inclusion (day 0)

    MRI lesions

  • duration of the disease

    At inclusion (day 0)

  • age at onset and progression

    At inclusion (day 0)

  • number of relapses

    At inclusion (day 0)

    Relapses

  • date of relapses

    At inclusion (day 0)

    Relapses

  • Treatment

    At inclusion (day 0)

Who could take part

Early (CIS/RIS) · 18 and over

Inclusion Criteria: * male or female subjects ; * Age ≥ 18 years; * subjects with MS defined by 2010 revised McDonald criteria or presenting a clinical isolated syndrome; * patients for which a blood draw and / or lumbar puncture to collect CSF is performed for diagnostic or therapeutic purpose; * affiliated to an health insurance system; * and who agree to participate in the study. Exclusion Criteria: * Pregnant or breastfeeding women, * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)

As registered. Criteria can change, so ask the trial team or your neurologist.

Contact details on the registry

About this trial

In the sponsor's words

The study aims at identifying the type of B and CD4 T cell subsets with pathogenic properties in the different clinical forms of multiple sclerosis. This research might open new therapeutic approaches for the treatment of multiple sclerosis particularly progressive MS.

Loading reviews and guidelines…

History

    1. Started

      Sept 2021

    2. Main results due

      Sept 2027

    3. Finished

      Sept 2027

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error